Dr. Reddy’s Laboratories to Engage in Investor Conferences in May-June 2025

Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.

On May 20, 2025, Dr. Reddy’s Laboratories announced its participation in upcoming investor conferences organized by Macquarie and Bank of America. These meetings, scheduled for late May and early June 2025, will take place in Paris, London, and Mumbai, and will involve in-person group meetings with institutional investors. This engagement signifies the company’s proactive approach to investor relations and its efforts to maintain transparency and communication with stakeholders.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories is a prominent pharmaceutical company based in Hyderabad, India. It specializes in the development and distribution of a wide range of pharmaceutical products, focusing on generic medications and active pharmaceutical ingredients. The company is listed on multiple stock exchanges, including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.

Average Trading Volume: 2,100,801

Technical Sentiment Signal: Buy

Current Market Cap: $11.9B

See more data about RDY stock on TipRanks’ Stock Analysis page.